Japan Approves Pioneering Regenerative Medicine Products Using iPS Cells

Japan's Ministry of Health, Labour and Welfare announced on Friday, the 6th, the conditional and time-limited approval for the production and sale of regenerative medicine products utilizing induced pluripotent stem cells (iPS cells), marking a global first. According to Ming Pao, the approved products include ReHeart, intended for severe heart failure, and Amchepry, designed for patients with Parkinson's disease. Local media reports suggest that these products are expected to be launched around the summer of this year.